Crinecerfont
Brand names: Crenessity Ā· Active ingredient: Crinecerfont
In short: CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
What is Crinecerfont used for?
CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
Crinecerfont dosage
Patients receiving CRENESSITY should continue glucocorticoid replacement therapy for the adrenal insufficiency associated with congenital adrenal hyperplasia .
Androstenedione levels can be assessed beginning four weeks after CRENESSITY initiation to inform reduction in glucocorticoid dosage as clinically indicated. Do not reduce the glucocorticoid dosage below that required for replacement therapy.
Recommended Dosage for Adults
The recommended CRENESSITY dosage for adults is 100 mg orally, twice daily with a meal in the morning and evening .
Recommended Dosage for Pediatric Patients
4
Years of Age and Older
The recommended CRENESSITY dosage for pediatric patients 4 years of age and older is weight-based and administered orally, twice daily with a meal in the morning and evening .
Table
1
:
Recommended
CRENESSITY
Weight-Based Dosage for Pediatric Patients 4 Years of
Age and
Older
Weight | Dosage Regimen
with a Meal
10 kg to less than 20 kg | 25 mg orally twice daily
20 kg to less than 55 kg | 50 mg orally twice daily
Greater than or equal to 55 kg | 100 mg orally twice daily
Adults
In adults, increase the CRENESSITY dosage to 200 mg orally, twice daily with a meal in the morning and evening when used concomitantly with strong CYP3A4 inducers .
Pediatric Patients 4 Years of Age and Older
In pediatric patients, increase the CRENESSITY dosage with a meal in the morning and evening when used concomitantly with strong CYP3A4 inducers as shown in Table 2 .
Table
2
:
Dosage Increase of
CRENESSITY for
Use with
Strong CYP3A4 Inducers
in Pediatric Patients
4 Years of Age and Older
Weight | Dosage Regimen
with a Meal
10 kg to less than 20 kg | 50 mg orally twice daily
20 kg to less than 55 kg | 100 mg orally twice daily
Greater than or equal to <55 kg | 200 mg orally twice daily
Adults
In adults, increase the CRENESSITY dosage to 200 mg orally with the evening meal when used concomitantly with moderate CYP3A4 inducers. The CRENESSITY dosage of 100 mg with the morning meal remains unchanged .
Pediatric Patients 4 Years of Age and Older
In pediatric patients, increase the CRENESSITY dosage with the evening meal when used concomitantly with moderate CYP3A4 inducers as shown in Table 3 .
Table
3
.
Dosage Increase of CRENESSITY for Use with Moderate CYP3A4 Inducers in Pediatric
Patients 4 Years of Age and Older
Dosage Regimen with a Meal
Weight | Morning Dose | Evening Dose
10 kg to less than 20 kg | 25 mg orally | 50 mg orally
20 kg to less than 55 kg | 50 mg orally | 100 mg orally
Greater than or equal to 55 kg | 100 mg orally | 200 mg orally
Administer CRENESSITY orally, twice daily, with a meal in the morning and evening .
CRENESSITY Capsules
Take CRENESSITY capsules orally and swallow whole with liquid. ā¦
How to take Crinecerfont ā instructions & advice from the label
Advise the patients and/or caregivers to read the FDA-approved patient labeling (Patient Information leaflet and CRENESSITY oral solution IFU, if applicable).
Administration Information
Counsel patients that CRENESSITY must be taken with a meal, without regard to fat or caloric content .
Drug Interactions
Inform patients that the CRENESSITY dosage will need to be increased if they are taking strong or moderate CYP3A4 inducers .
Hypersensitivity Reactions
Advise patients to seek prompt medical attention if signs or symptoms of hypersensitivity reactions occur. Advise patients who have had signs or symptoms of systemic hypersensitivity reactions to CRENESSITY that they should not receive CRENESSITY .
Acute Adrenal Insufficiency or Adrenal Crisis
w
ith Inadequate Concomitant Glucocorticoid Therapy
Inform patients that they should continue glucocorticoids when taking CRENESSITY. Counsel patients that any adjustment of glucocorticoid doses should be done under the guidance of their health care provider. Counsel patients about the continued need for stress dose glucocorticoids during times of increased cortisol need (e.g., during illness) . ā¦
Warnings & precautions
Do not take this medicine if: CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY. Reactions have included throat tightness, angioedema, and generalized rash .
A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY.
If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.
Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement.
Acute adrenal insufficiency or adrenal crisis, which can potentially be fatal or life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures.
Any adjustment of daily glucocorticoid dosage after initiation of CRENESSITY should be performed under the supervision of a health care provider. Use glucocorticoid stress doses in case of increased cortisol need (e.g., acute intercurrent illness, serious trauma, surgical procedures).
In the placebo-controlled clinical study of adults with classic CAH, the incidence of adrenal crisis was 1.6% in subjects treated with CRENESSITY and 0% in subjects treated with placebo. In the placebo-controlled clinical study of pediatric subjects with classic CAH, there were no events of adrenal crisis.
Crinecerfont side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions
Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults with
Congenital Adrenal Hyperplasia (
CAH)
The safety of CRENESSITY in adults was assessed in Study 1, a randomized, double-blind, placebo-controlled study of 182 adults aged 18 to 58 years with classic CAH due to 21-hydroxylase deficiency. A total of 122 subjects received CRENESSITY 100 mg twice daily and 59 subjects received placebo twice daily for up to 24 weeks .
Adverse Reactions Leading to Discontinuation of Treatment
A total of 3% of CRENESSITY-treated subjects and no placebo-treated subjects discontinued treatment because of adverse reactions of restlessness, apathy, dyspepsia, nausea, and vomiting.
Commonly Observed Adverse Reactions
Adverse reactions that occurred in ā„4% of CRENESSITY-treated subjects and more frequently than in placebo-treated subjects are presented in Table 4. ā¦
Drug interactions
Strong CYP3A4 Inducers
Increase CRENESSITY morning and evening dosages 2-fold when CRENESSITY is used concomitantly with a strong CYP3A4 inducer .
Moderate CYP3A4 Inducers
Increase CRENESSITY evening dosage 2-fold when CRENESSITY is used concomitantly with a moderate CYP3A4 inducer. Do not increase the morning dosage .
Mechanism of Drug Interaction and Clinical Effect
CRENESSITY is a CYP3A4 substrate. Concomitant use of CRENESSITY with a strong or moderate CYP3A4 inducer decreases crinecerfont exposure , which may reduce CRENESSITY efficacy.
About this medicine
CRENESSITY contains crinecerfont, a selective corticotropin-releasing factor type 1 receptor antagonist, present as crinecerfont free base, with the chemical name, 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl. Crinecerfont free base is the S-enantiomer with an enantiomeric excess of at least 99.7%. Its molecular formula is C27H28ClFN2OS, and its molecular weight is 483.04 g/mol with the following structure:
CRENESSITY Capsules
CRENESSITY capsules are intended for oral administration only. Each capsule contains 25 mg, 50 mg, or 100 mg of crinecerfont free base. Inactive ingredients include lauroyl polyoxyl-32 glycerides, medium chain triglycerides, propylene glycol dicaprylate/dicaprate, and Vitamin E polyethylene glycol succinate. The capsule shell contains gelatin, glycerin, red iron oxide, Sorbitol glycerin blend, titanium dioxide, and yellow iron oxide.
CRENESSITY Oral Solution
The oral solution formulation contains 50 mg/mL of crinecerfont free base. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fd3a6fbd-9137-428a-ba46-df6606f07d28. Read the full official label on DailyMed.